PRODUCT IDENTIFICATION
H.S. CODE
TOXICITY
SYNONYMS
c12N(c3c(cccc3)CC(c1cccc2)=O)C(N)=O
Anticonvulsant, Antiepileptic, Peripheral Nervous System Agent, Psychotropic, Tranquilizing Agent
PHYSICAL AND CHEMICAL PROPERTIES
218 - 224 C
REFRACTIVE INDEX
Stable under ordinary conditions.
GENERAL DESCRIPTION & EXTERNAL LINKS
Wikipedia Linking: http://en.wikipedia.org/wiki/Oxcarbazepine
http://www.sciencedirect.com/
A new synthesis of oxcarbazepine using a Friedel–Crafts
cyclization strategy: A novel, simple, and straightforward process for the large-scale synthesis of
oxcarbazepine, the active ingredient of Trileptal®, a medicine for
the treatment of epilepsy, has been developed. Starting from readily available
1,3-dihydro-1-phenyl-2H-indol-2-one, a Friedel–Crafts cyclization
strategy provides a direct route to the tricyclic framework of the target
molecule. Crucial to the success of the strategy was the choice of the proper
nitrogen-protecting group....
http://www.sciencedirect.com/
Oxcarbazepine-induced hyponatremia, a cross-sectional
study: In order to estimate the frequency of hyponatremia in patients treated with
oxcarbazepine (OxCZ), a cross-sectional study was carried out. 21 of 41 patients
being treated with the drug were found to be hyponatremic (serum sodium levels
<135 mmol/l). None was found to be hypernatremic (serum sodium levels >145
mmol/l). A non-significant trend towards increasing frequency of hyponatremia
with increasing age was observed. Patients treated with dosages above 30
mg/kg/day had a significantly higher risk of becoming hyponatremic.....
http://www2.cochrane.org/
Oxcarbazepine in the maintenance treatment of bipolar
disorder: Some studies have suggested that oxcarbazepine, an anti-convulsant, may have
a role in preventing episode recurrence in bipolar affective disorder. This
systematic review investigated the efficacy and acceptability of oxcarbazepine
compared to placebo and other agents in the maintenance treatment of bipolar
disorder. Two randomised controlled trials were found that met the
methodological inclusion criteria. However, in both cases, data were reported
with insufficient clarity to be confidently extracted for inclusion in a
meta-analysis. Currently, there is insufficient evidence on which to base any
recommendations on the use of oxcarbazepine in the maintenance treatment of
bipolar illness, either in monotherapy or as an adjunctive treatment. There is
need for good quality randomised controlled trials examining the efficacy and
acceptability of oxcarbazepine in the maintenance treatment of bipolar disorder.....
ANTICONVULSANTS
|
|
APPEARANCE
99.0% min
MELTING POINT
218 - 224 C
LOSS ON DRYING
0.5% max
